Monika Bratova1,2, Bara Karlinova3, Jana Skrickova1,2, Milos Pesek4,5, Vitezslav Kolek6,7, Leona Koubkova8,9, Michal Hrnciarik10,11, Jana Krejci12, Magda Barinova13, Libor Havel14, Ivona Grygarkova15, Kristian Brat16,2. 1. Department of Respiratory Diseases, University Hospital Brno, Brno, Czech Republic. 2. Faculty of Medicine, Masaryk University, Brno, Czech Republic. 3. Faculty of Economics and Administration, Masaryk University, Brno, Czech Republic. 4. Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic. 5. Faculty of Medicine, Charles University in Prague, Pilsen, Czech Republic. 6. Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic. 7. Palacky University, Olomouc, Czech Republic. 8. Department of Pneumology, University Hospital Motol, Prague, Czech Republic. 9. Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. 10. Department of Pneumology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. 11. Faculty of Medicine, Charles University in Prague, Hradec Kralove, Czech Republic. 12. Department of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic. 13. Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic. 14. Department of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic. 15. Department of Respiratory Diseases, Prostejov Hospital, Prostejov, Czech Republic. 16. Department of Respiratory Diseases, University Hospital Brno, Brno, Czech Republic kristian.brat@seznam.cz.
Abstract
AIM: To compare survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with modern-era drugs (antifolates, antiangiogenics, tyrosine kinase and anaplastic lymphoma kinase inhibitors, immunotherapy) with treatment initiation in 2011-12 and 2015-16, respectively. PATIENTS AND METHODS: Prospective data from Czech TULUNG Registry (960 patients from 2011-12 and 512 patients from 2015-16) were analyzed. Kaplan-Meier analysis was used to estimate overall survival (OS) and progression-free survival (PFS); Cox proportional hazards model to assess factors associated with 2-year survival. RESULTS: Survival at 2 years was more frequent in cohort 2015-16 compared to cohort 2011-12 (43.2% vs. 24% for adenocarcinoma; p<0.001 and 28.7% vs. 11.8% for squamous-cell lung carcinoma; p=0.002). Assignment to cohort 2015-16 and treatment multilinearity (two or more lines in sequence) were associated with higher probability of 2-year survival (hazard ratio=0.666 and hazard ratio=0.597; p<0.001). Comparison of 2-year survivors from both cohorts showed no differences. CONCLUSION: Survival at 2 years probability in stage IIIB-IV NSCLC doubled between 2011-12 and 2015-16; advanced-stage NSCLC may be considered a chronic disease in a large proportion of patients. Copyright
AIM: To compare survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with modern-era drugs (antifolates, antiangiogenics, tyrosine kinase and anaplastic lymphoma kinase inhibitors, immunotherapy) with treatment initiation in 2011-12 and 2015-16, respectively. PATIENTS AND METHODS: Prospective data from Czech TULUNG Registry (960 patients from 2011-12 and 512 patients from 2015-16) were analyzed. Kaplan-Meier analysis was used to estimate overall survival (OS) and progression-free survival (PFS); Cox proportional hazards model to assess factors associated with 2-year survival. RESULTS: Survival at 2 years was more frequent in cohort 2015-16 compared to cohort 2011-12 (43.2% vs. 24% for adenocarcinoma; p<0.001 and 28.7% vs. 11.8% for squamous-cell lung carcinoma; p=0.002). Assignment to cohort 2015-16 and treatment multilinearity (two or more lines in sequence) were associated with higher probability of 2-year survival (hazard ratio=0.666 and hazard ratio=0.597; p<0.001). Comparison of 2-year survivors from both cohorts showed no differences. CONCLUSION: Survival at 2 years probability in stage IIIB-IV NSCLC doubled between 2011-12 and 2015-16; advanced-stage NSCLC may be considered a chronic disease in a large proportion of patients. Copyright
Authors: Jie Ting; PharmD Tien Ho; Pin Xiang; Amanda Sugay; Maher Abdel-Sattar; Leslie Wilson Journal: Value Health Date: 2015-06-22 Impact factor: 5.725
Authors: Scott N Gettinger; Lyudmila A Bazhenova; Corey J Langer; Ravi Salgia; Kathryn A Gold; Rafael Rosell; Alice T Shaw; Glen J Weiss; Meera Tugnait; Narayana I Narasimhan; David J Dorer; David Kerstein; Victor M Rivera; Timothy Clackson; Frank G Haluska; David Ross Camidge Journal: Lancet Oncol Date: 2016-11-08 Impact factor: 41.316
Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Vincent A Miller; Mark G Kris; Neelam Shah; Jyoti Patel; Christopher Azzoli; Jorge Gomez; Lee M Krug; William Pao; Naiyer Rizvi; Barbara Pizzo; Leslie Tyson; Ennapadam Venkatraman; Leah Ben-Porat; Natalie Memoli; Maureen Zakowski; Valerie Rusch; Robert T Heelan Journal: J Clin Oncol Date: 2004-03-15 Impact factor: 44.544
Authors: D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw Journal: Lancet Oncol Date: 2012-09-04 Impact factor: 41.316
Authors: Sharon L Sanders; Erin O Bantum; Jason E Owen; Andrea A Thornton; Annette L Stanton Journal: Psychooncology Date: 2010-05 Impact factor: 3.894
Authors: Kristian Brat; Monika Bratova; Jana Skrickova; Magda Barinova; Karolina Hurdalkova; Milos Pesek; Libor Havel; Leona Koubkova; Michal Hrnciarik; Jana Krejci; Ondrej Fischer; Milada Zemanova; Helena Coupkova; Martin Svaton Journal: Thorac Cancer Date: 2020-10-05 Impact factor: 3.500